Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer-Fighting CAR-T cells take on tough kidney disease in first human trial

NCT ID NCT07266181

Recruiting now Disease control Sponsor: The First Affiliated Hospital of Air Force Medicial University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether a personalized immune cell therapy called CAR-T can safely treat a severe, hard-to-control kidney condition called refractory membranous nephropathy. Five adults with confirmed disease will receive a single infusion of engineered cells after mild chemotherapy, then be monitored closely for side effects and kidney improvement over one year. The main goal is to check safety, but researchers will also see if the treatment reduces protein in the urine and improves kidney function.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY MEMBRANOUS NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

membranous glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

REFRACTORY MEMBRANOUS NEPHROPATHY

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Department of Nephrology, Xijing Hospital

    RECRUITING

    Xi'an, China, 710012, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••